The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1
FcγRIIa is an activating FcγR, unique to humans and non-human primates. It induces antibody-dependent proinflammatory responses and exists predominantly as FcγRIIa1. A unique splice variant, we designated FcγRIIa3, has been reported to be associated with anaphylactic reactions to intravenous immunog...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01809/full |
id |
doaj-8f1f72bd8c604a6cb933aa7bfdb9d2cc |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jessica C. Anania Jessica C. Anania Halina M. Trist Catherine S. Palmer Catherine S. Palmer Peck Szee Tan Betty P. Kouskousis Betty P. Kouskousis Alicia M. Chenoweth Alicia M. Chenoweth Stephen J. Kent Stephen J. Kent Stephen J. Kent Graham A. Mackay Alberta Hoi Rachel Koelmeyer Charlotte Slade Charlotte Slade Charlotte Slade Charlotte Slade Vanessa L. Bryant Vanessa L. Bryant Vanessa L. Bryant Vanessa L. Bryant Philip D. Hodgkin Philip D. Hodgkin Pei Mun Aui Pei Mun Aui Menno C. van Zelm Menno C. van Zelm Bruce D. Wines Bruce D. Wines Bruce D. Wines P. Mark Hogarth P. Mark Hogarth P. Mark Hogarth |
spellingShingle |
Jessica C. Anania Jessica C. Anania Halina M. Trist Catherine S. Palmer Catherine S. Palmer Peck Szee Tan Betty P. Kouskousis Betty P. Kouskousis Alicia M. Chenoweth Alicia M. Chenoweth Stephen J. Kent Stephen J. Kent Stephen J. Kent Graham A. Mackay Alberta Hoi Rachel Koelmeyer Charlotte Slade Charlotte Slade Charlotte Slade Charlotte Slade Vanessa L. Bryant Vanessa L. Bryant Vanessa L. Bryant Vanessa L. Bryant Philip D. Hodgkin Philip D. Hodgkin Pei Mun Aui Pei Mun Aui Menno C. van Zelm Menno C. van Zelm Bruce D. Wines Bruce D. Wines Bruce D. Wines P. Mark Hogarth P. Mark Hogarth P. Mark Hogarth The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1 Frontiers in Immunology Fc receptors common variable immunodeficiency immunodeficiency systemic lupus erythematosus immune complex non-human primates |
author_facet |
Jessica C. Anania Jessica C. Anania Halina M. Trist Catherine S. Palmer Catherine S. Palmer Peck Szee Tan Betty P. Kouskousis Betty P. Kouskousis Alicia M. Chenoweth Alicia M. Chenoweth Stephen J. Kent Stephen J. Kent Stephen J. Kent Graham A. Mackay Alberta Hoi Rachel Koelmeyer Charlotte Slade Charlotte Slade Charlotte Slade Charlotte Slade Vanessa L. Bryant Vanessa L. Bryant Vanessa L. Bryant Vanessa L. Bryant Philip D. Hodgkin Philip D. Hodgkin Pei Mun Aui Pei Mun Aui Menno C. van Zelm Menno C. van Zelm Bruce D. Wines Bruce D. Wines Bruce D. Wines P. Mark Hogarth P. Mark Hogarth P. Mark Hogarth |
author_sort |
Jessica C. Anania |
title |
The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1 |
title_short |
The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1 |
title_full |
The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1 |
title_fullStr |
The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1 |
title_full_unstemmed |
The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1 |
title_sort |
rare anaphylaxis-associated fcγriia3 exhibits distinct characteristics from the canonical fcγriia1 |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2018-08-01 |
description |
FcγRIIa is an activating FcγR, unique to humans and non-human primates. It induces antibody-dependent proinflammatory responses and exists predominantly as FcγRIIa1. A unique splice variant, we designated FcγRIIa3, has been reported to be associated with anaphylactic reactions to intravenous immunoglobulins (IVIg) therapy. We aim to define the functional consequences of this FcγRIIa variant associated with adverse responses to IVIg therapy and evaluate the frequency of associated SNPs. FcγRIIa forms from macaque and human PBMCs were investigated for IgG-subclass specificity, biochemistry, membrane localization, and functional activity. Disease-associated SNPs were analyzed by sequencing genomic DNA from 224 individuals with immunodeficiency or autoimmune disease. FcγRIIa3 was identified in macaque and human PBMC. The FcγRIIa3 is distinguished from the canonical FcγRIIa1 by a unique 19-amino acid cytoplasmic insertion and these two FcγRIIa forms responded distinctly to antibody ligation. Whereas FcγRIIa1 was rapidly internalized, FcγRIIa3 was retained longer at the membrane, inducing greater calcium mobilization and cell degranulation. Four FCGR2A SNPs were identified including the previously reported intronic SNP associated with anaphylaxis, but in only 1 of 224 individuals. The unique cytoplasmic element of FcγRIIa3 delays internalization and is associated with enhanced cellular activation. The frequency of the immunodeficiency-associated SNP varies between disease populations but interestingly occurred at a lower frequency than previously reported. None-the-less enhanced FcγRIIa3 function may promote a proinflammatory environment and predispose to pathological inflammatory responses. |
topic |
Fc receptors common variable immunodeficiency immunodeficiency systemic lupus erythematosus immune complex non-human primates |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2018.01809/full |
work_keys_str_mv |
AT jessicacanania therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT jessicacanania therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT halinamtrist therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT catherinespalmer therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT catherinespalmer therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT peckszeetan therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT bettypkouskousis therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT bettypkouskousis therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT aliciamchenoweth therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT aliciamchenoweth therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT stephenjkent therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT stephenjkent therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT stephenjkent therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT grahamamackay therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT albertahoi therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT rachelkoelmeyer therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT philipdhodgkin therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT philipdhodgkin therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT peimunaui therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT peimunaui therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT mennocvanzelm therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT mennocvanzelm therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT brucedwines therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT brucedwines therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT brucedwines therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT pmarkhogarth therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT pmarkhogarth therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT pmarkhogarth therareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT jessicacanania rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT jessicacanania rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT halinamtrist rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT catherinespalmer rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT catherinespalmer rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT peckszeetan rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT bettypkouskousis rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT bettypkouskousis rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT aliciamchenoweth rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT aliciamchenoweth rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT stephenjkent rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT stephenjkent rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT stephenjkent rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT grahamamackay rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT albertahoi rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT rachelkoelmeyer rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT charlotteslade rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT vanessalbryant rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT philipdhodgkin rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT philipdhodgkin rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT peimunaui rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT peimunaui rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT mennocvanzelm rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT mennocvanzelm rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT brucedwines rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT brucedwines rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT brucedwines rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT pmarkhogarth rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT pmarkhogarth rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 AT pmarkhogarth rareanaphylaxisassociatedfcgriia3exhibitsdistinctcharacteristicsfromthecanonicalfcgriia1 |
_version_ |
1725957842561662976 |
spelling |
doaj-8f1f72bd8c604a6cb933aa7bfdb9d2cc2020-11-24T21:32:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-08-01910.3389/fimmu.2018.01809394759The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1Jessica C. Anania0Jessica C. Anania1Halina M. Trist2Catherine S. Palmer3Catherine S. Palmer4Peck Szee Tan5Betty P. Kouskousis6Betty P. Kouskousis7Alicia M. Chenoweth8Alicia M. Chenoweth9Stephen J. Kent10Stephen J. Kent11Stephen J. Kent12Graham A. Mackay13Alberta Hoi14Rachel Koelmeyer15Charlotte Slade16Charlotte Slade17Charlotte Slade18Charlotte Slade19Vanessa L. Bryant20Vanessa L. Bryant21Vanessa L. Bryant22Vanessa L. Bryant23Philip D. Hodgkin24Philip D. Hodgkin25Pei Mun Aui26Pei Mun Aui27Menno C. van Zelm28Menno C. van Zelm29Bruce D. Wines30Bruce D. Wines31Bruce D. Wines32P. Mark Hogarth33P. Mark Hogarth34P. Mark Hogarth35Immune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaMonash Micro Imaging, Monash University, Clayton, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaMonash Micro Imaging, Monash University, Clayton, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, AustraliaDepartment of Microbiology and Immunology, University of Melbourne, Parkville, VIC, AustraliaMelbourne Sexual Health Centre, Central Clinical School, Monash University, Melbourne, VIC, AustraliaARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, VIC, AustraliaDepartment of Pharmacology & Therapeutics, The University of Melbourne, Parkville, VIC, AustraliaDepartment of Medicine, Monash Medical Centre, Clayton, VIC, AustraliaDepartment of Medicine, Monash Medical Centre, Clayton, VIC, AustraliaDepartment of Medical Biology, The University of Melbourne, Parkville, VIC, Australia0Walter and Eliza Hall Institute for Medical Research, Royal Melbourne Hospital, Parkville, VIC, Australia1Department of Clinical Immunology and Allergy, Royal Melbourne Hospital, Parkville, VIC, Australia2The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies, Melbourne, VIC, AustraliaDepartment of Medical Biology, The University of Melbourne, Parkville, VIC, Australia0Walter and Eliza Hall Institute for Medical Research, Royal Melbourne Hospital, Parkville, VIC, Australia1Department of Clinical Immunology and Allergy, Royal Melbourne Hospital, Parkville, VIC, Australia2The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies, Melbourne, VIC, AustraliaDepartment of Medical Biology, The University of Melbourne, Parkville, VIC, Australia0Walter and Eliza Hall Institute for Medical Research, Royal Melbourne Hospital, Parkville, VIC, AustraliaDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia2The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies, Melbourne, VIC, AustraliaDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia2The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies, Melbourne, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia3Department of Pathology, The University of Melbourne, Parkville, VIC, AustraliaImmune Therapies Group, Burnet Institute, Melbourne, VIC, AustraliaDepartment of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia3Department of Pathology, The University of Melbourne, Parkville, VIC, AustraliaFcγRIIa is an activating FcγR, unique to humans and non-human primates. It induces antibody-dependent proinflammatory responses and exists predominantly as FcγRIIa1. A unique splice variant, we designated FcγRIIa3, has been reported to be associated with anaphylactic reactions to intravenous immunoglobulins (IVIg) therapy. We aim to define the functional consequences of this FcγRIIa variant associated with adverse responses to IVIg therapy and evaluate the frequency of associated SNPs. FcγRIIa forms from macaque and human PBMCs were investigated for IgG-subclass specificity, biochemistry, membrane localization, and functional activity. Disease-associated SNPs were analyzed by sequencing genomic DNA from 224 individuals with immunodeficiency or autoimmune disease. FcγRIIa3 was identified in macaque and human PBMC. The FcγRIIa3 is distinguished from the canonical FcγRIIa1 by a unique 19-amino acid cytoplasmic insertion and these two FcγRIIa forms responded distinctly to antibody ligation. Whereas FcγRIIa1 was rapidly internalized, FcγRIIa3 was retained longer at the membrane, inducing greater calcium mobilization and cell degranulation. Four FCGR2A SNPs were identified including the previously reported intronic SNP associated with anaphylaxis, but in only 1 of 224 individuals. The unique cytoplasmic element of FcγRIIa3 delays internalization and is associated with enhanced cellular activation. The frequency of the immunodeficiency-associated SNP varies between disease populations but interestingly occurred at a lower frequency than previously reported. None-the-less enhanced FcγRIIa3 function may promote a proinflammatory environment and predispose to pathological inflammatory responses.https://www.frontiersin.org/article/10.3389/fimmu.2018.01809/fullFc receptorscommon variable immunodeficiencyimmunodeficiencysystemic lupus erythematosusimmune complexnon-human primates |